Affimed in the spotlight (part II, ASH 2022 update)

Key opinion leader insights on latest AFMD data

Following up on our boutique update on Affimed (AFMD) earlier this month, last week Slingshot Insights had a call with a lymphoma key opinion leader (KOL) on the Company’s AFM13+NK data presented at ASH earlier in December. From an efficacy & toxicity standpoint, data looked fantastic. The KOL had low expectations given that he treated patients on the o…